Vector vaccination and vector targeted chemotherapy in solid tumors

被引:0
作者
Akbulut, H. [1 ]
Tang, Y. [2 ]
Deisseroth, A. [3 ]
机构
[1] Ankara Univ, Sch Med, Dept Med Oncol, TR-06100 Ankara, Turkey
[2] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA 92103 USA
[3] US FDA, Silver Spring, MD USA
来源
JOURNAL OF BUON | 2009年 / 14卷
关键词
adenoviral vectors; cytosine deaminase; gene therapy; tumor vaccines; SUICIDE GENE-THERAPY; L-PLASTIN PROMOTER; CYTOSINE DEAMINASE; DENDRITIC CELLS; PHASE-I; RECURRENT HEAD; CANCER; ADENOVIRUS; OVARIAN; 5-FLUOROURACIL;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Gene therapy is one of the promising treatment modalities in cancer therapy. The current gene therapy modalities are mainly focused on the introduction of suppressed tumor suppressor genes into cancer cells, modulation of anti-tumoral immune response, and the suicide gene therapy by introducing pro-drug-activating enzyme genes into the tumor cells. Currently, various gene therapy trials arc, being conducted in cancer patients. However the early results of these trials conducted so far are not so encouraging. Combination of gene therapy strategies with conventional treatment modalities such as chemotherapy, immunotherapy or radiotherapy has yielded encouraging results in experimental models and early clinical trials.
引用
收藏
页码:S141 / S146
页数:6
相关论文
共 32 条
  • [1] Vector targeting makes 5-fluorouracil chemotherapy less toxic and more effective in animal models of epithelial neoplasms
    Akbulut, H
    Tang, YC
    Maynard, J
    Zhang, LX
    Pizzorno, G
    Deisseroth, A
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (22) : 7738 - 7746
  • [2] Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon
    Akbulut, H
    Zhang, LX
    Tang, YC
    Deisseroth, A
    [J]. CANCER GENE THERAPY, 2003, 10 (05) : 388 - 395
  • [3] Chemotherapy targeted to cancer tissue potentiates antigen-specific immune response induced by vaccine for in vivo antigen loading and activation of dendritic cells
    Akbulut, Hakan
    Tang, Yucheng
    Akbulut, K. Gonca
    Albert, Jonathan Maynard
    Deisseroth, Albert
    [J]. MOLECULAR THERAPY, 2008, 16 (10) : 1753 - 1760
  • [4] Antitumor immune response induced by i.t. injection of vector-activated dendritic cells and chemotherapy suppresses metastatic breast cancer
    Akbulut, Hakan
    Tang, Yucheng
    Akbulut, K. Gonca
    Maynard, Jonathan
    Zhang, Lixin
    Deisseroth, Albert
    [J]. MOLECULAR CANCER THERAPEUTICS, 2006, 5 (08) : 1975 - 1985
  • [5] Replicative adenoviruses for cancer therapy
    Alemany, R
    Balagué, C
    Curiel, DT
    [J]. NATURE BIOTECHNOLOGY, 2000, 18 (07) : 723 - 727
  • [6] Cytosine deaminase suicide gene therapy for peritoneal carcinomatosis
    Bentires-Alj, M
    Hellin, AC
    Lechanteur, C
    Princen, F
    Lopez, M
    Fillet, G
    Gielen, J
    Merville, MP
    Bours, V
    [J]. CANCER GENE THERAPY, 2000, 7 (01) : 20 - 26
  • [7] A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer
    Buller, RE
    Runnebaum, IB
    Karlan, BY
    Horowitz, JA
    Shahin, M
    Buekers, T
    Petrauskas, S
    Kreienberg, R
    Slamon, D
    Pegram, M
    [J]. CANCER GENE THERAPY, 2002, 9 (07) : 553 - 566
  • [8] Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells
    Chung, I
    Schwartz, PE
    Crystal, RG
    Pizzorno, G
    Leavitt, J
    Deisseroth, AB
    [J]. CANCER GENE THERAPY, 1999, 6 (02) : 99 - 106
  • [9] Freedman RS, 2000, CLIN CANCER RES, V6, P2268
  • [10] Ganly I, 2000, CLIN CANCER RES, V6, P798